CRISPR (an acronym for Clustered Regularly Interspaced Short Palindromic Repeats) is a name we commonly hear in association with gene editing.The ARK Innovation ETF recently sold some of its shares of Editas Medicine ( NASDAQ:EDIT). There are many different, other methods to produce GMOs, however. August 9, 2021.Gene editing is used for many purposes, one of which is for the creation of GMOs. Medline today announced that it has signed more than 450 new customer contracts during the first half of 2021 for its Post-Acute Solutions Program, aimed at offering technology-based quality and workf. Medline signs 450-plus long-term care provider contracts for technology-based workforce solutions. Selling before the news?August 10, 2021.
Gene'S Hine Inc Trial Has Progressed
The ARK Genomic Revolution ETF owns more than 9.5 million shares of the gene-editing pioneer. While the ARK Innovation ETF has sold some of its position in the biotech, it still owns more than 4 million shares of Editas. On the company's second-quarter conference call, Chief Medical Officer Lisa Michaels said that Editas was "very happy with how this trial has progressed during this year." In the press release announcing the upcoming presentation, Michaels stated that the company was eager to share its "progress toward developing a transformative gene editing medicine for people living with CEP290-related retinal degeneration."It doesn't seem like Wood is anticipating really bad news with Editas' data, though. 29 from its phase 1/2 clinical study evaluating CRISPR gene-editing therapy EDIT-101 in treating rare genetic eye disorder Leber congenital amaurosis 10.As would be expected, Editas hasn't given any clear hints about how good its data might be. Editas is scheduled to present data on Sept.
The companies think that they could be on track to file for regulatory approvals for CTX001 as soon as the second half of 2023.In addition, CRISPR Therapeutics is moving forward with early clinical testing of three other gene-editing cancer cell therapy candidates. However, Wood wouldn't buy CRISPR Therapeutics if she didn't have great expectations for the company's pipeline.CRISPR Therapeutics and its big partner, Vertex Pharmaceuticals, are evaluating gene-editing therapy CTX001 in treating rare blood disorders beta-thalassemia and sickle cell disease. The stock is more than 40% below its highs from earlier this year. So has the ARK Innovation ETF.You might say that Wood has gone dumpster diving with these purchases of CRISPR Therapeutics.
This method offers more precise editing of genes than other CRISPR gene-editing therapies. The company's technology uses a CRISPR protein combined with a base-editing enzyme. However, that could change soon: Beam expects to file an Investigational New Drug application to begin an early-stage clinical study of BEAM-101 in treating beta-thalassemia and sickle cell disease in 2021.Wood likes the long-term potential of Beam's base editing approach. The company doesn't have any programs in clinical testing yet.
0 kommentar(er)
